Effect of pioglitazone on cardiometabolic profiles and safety in patients with type 2 diabetes undergoing percutaneous coronary artery intervention: a prospective, multicenter, randomized trial

Koichi Node(Saga University), Atsushi Tanaka(Friends United), Tomohiro Kawasaki(Koga Hospital), Teruo Inoue(Dokkyo Medical University), Mitsuhiro Shimomura(Saga University), Hitoshi Nakashima(National Hospital Organization), Sho Komukai(The University of Osaka), Kōichi Nakao(Kanazawa Seiryo University), Hiroyoshi Yokoi(Kurume University), Takafumi Ueno(Kurume University), Yoshihiro Iwasaki(Koga Hospital), Yoshisato Shibata, Motoko Tago(Saga University), Atsushi Kawaguchi(Kyoto University), Kenji Horiuchi(Kyoto Medical Center), Masahiro Tamashiro(Saga University), Shigeru Toyoda(Dokkyo Medical University), Yutaka Hikichi(Saga University)
Heart and Vessels
February 27, 2018
10.1007/s00380-018-1143-3
Cited by 11

Related Papers

Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure.
|Circulation|1994|1.3k
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI
|JAMA|2019|848
Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
|Nature Medicine|2002|722
JCS 2018 Guideline on Diagnosis and Treatment of Acute Coronary Syndrome
|Circulation Journal|2019|582
Impact of Dual Lipid-Lowering Strategy With Ezetimibe and Atorvastatin on Coronary Plaque Regression in Patients With Percutaneous Coronary Intervention
|Journal of the American College of Cardiology|2015|453